RT Journal Article
SR Electronic
T1 A gene locus that controls expression of <em>ACE2</em> in virus infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.26.20080408
DO 10.1101/2020.04.26.20080408
A1 Ansari, M. Azim
A1 Marchi, Emanuele
A1 Ramamurthy, Narayan
A1 Aschenbrenner, Dominik
A1 Hackstein, Carl-Philipp
A1 ,
A1 ,
A1 Bowden, Rory
A1 Sharma, Eshita
A1 Pedergnana, Vincent
A1 Venkateswaran, Suresh
A1 Kugathasan, Subra
A1 Mo, Angela
A1 Gibson, Greg
A1 McLauchlan, John
A1 Barnes, Eleanor
A1 Baillie, John Kenneth
A1 Teichmann, Sarah
A1 Mentzer, Alex
A1 Todd, John
A1 Knight, Julian
A1 Uhlig, Holm
A1 Klenerman, Paul
YR 2020
UL http://medrxiv.org/content/early/2020/04/29/2020.04.26.20080408.abstract
AB The SARS-CoV-2 pandemic has resulted in widespread morbidity and mortality globally, but with widely variable outcomes. The development of severe disease and mortality is higher in older individuals, males and those with other co-morbidities, and may vary across ethnic groups. However, so far, no host genetic factor has been clearly associated with susceptibility and development of severe disease. To understand the impact of host genetics on expression of ACE2 (SARS-CoV-2 receptor) during RNA virus infection we performed a GWAS for ACE2 expression in HCV-infected liver tissue from 195 individuals. We discovered that polymorphisms in the host IFNL region which control expression of IFNL3 and IFNL4 modulate ACE2 expression. ACE2 expression was regulated additionally by age, with a subsidiary effect of co-morbidity. The IFNL locus controlled expression of a gene network incorporating many well-known interferon-stimulated genes which anti-correlated with ACE2 transcript levels. The same anti-correlation was found in the gastrointestinal tract, a site of SARS-CoV-2 replication where inflammation driven interferon-stimulated genes are negatively correlated with ACE2 expression. The interferon dependent regulation of ACE2 was identified in a murine model of SARS-CoV-1 suggesting conserved regulation of ACE2 across species. Polymorphisms in the IFNL region, as well as age, may impact not only on classical antiviral responses but also on ACE2 with potential consequences for clinical outcomes in distinct ethnic groups and with implications for therapeutic interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors would like to thank Gilead Sciences for the provision of samples and data from the BOSON clinical study for use in these analyses. The authors would also like to thank HCV Research UK (funded by the Medical Research Foundation) for their assistance in handling and coordinating the release of samples for these analyses. The authors would also like to thank ISARIC-4C investigators for their discussion and contributions to this study. This work was funded by a grant from the Medical Research Council (MR/K01532X/1 – STOP-HCV Consortium). The work was supported by Core funding to the Wellcome Centre for Human Genetics provided by the Wellcome Trust (203141/Z/16/Z). This work was also supported by the Medical Research Council [grant number MC_PC_19059] and a strategic award from the Wellcome Trust (211276/Z/18/Z – WSSS). PK, is supported as a Wellcome Trust Senior Investigator (WT 109965MA) and an NIHR Senior Investigator. PK is affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford. EB was funded by the Medical Research Council UK, the Oxford NIHR Biomedical Research Centre and is an NIHR Senior Investigator. The work was also supported by the NIHR Biomedical Research Centre, Oxford. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesInformation on access to individual-level genotype and sequence data is available here: http://www.stop-hcv.ox.ac.uk/data-access. http://www.stop-hcv.ox.ac.uk/data-access